EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Effectiveness of tick-borne encephalitis vaccination in Latvia, 2018–2020: an observational study

Dace Zavadska, Zane Freimane, Guntis Karelis, Ineta Ermina, Lisa R Harper, Cody Bender, Pingping Zhang, Frederick J Angulo, Wilhelm Erber, Antra Bormane, Evija Gutmane, Zane A Litauniece und 4 weitere

Clinical Microbiology and Infection · 2023

DOI: 10.1016/j.cmi.2023.06.028 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical Microbiology and Infection, 2023. Verfasst von Dace Zavadska und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Children's Clinical University Hospital, Rīga Stradinš University, Riga, Latvia. Hauptthemen laut MEDLINE: Encephalitis, Tick-Borne, Encephalitis Viruses, Tick-Borne, Viral Vaccines, Antibodies, Viral. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Tick-borne encephalitis (TBE) is an infection by the tick-borne encephalitis virus (TBEV) that results in symptoms of central nervous system inflammation. TBE is endemic in Latvia and other European countries. TBE vaccines are commonly used in Latvia, but vaccine effectiveness estimates are limited. METHODS: Study staff at Rīga Stradinš University conducted nationwide active surveillance for TBEV infections. Serum and cerebrospinal fluid were ELISA-tested for TBEV-specific IgG and IgM antibodies. Vaccination history was collected by interview and medical record review. Utilizing data from surveillance and population surveys, vaccine effectiveness (with 95% CIs) and cases averted were estimated using the screening method. RESULTS: There were 587 laboratory-identified TBE cases from 2018 to 2020; 98.1% (576/587) were unvaccinated, 1.5% (9/587) were unknown or partially vaccinated, and 0.3% (2/587) were fully vaccinated (three-dose primary series and appropriately timed boosters). TBE resulted in the death of 1.7% (10/587) of TBE cases. TBE vaccine history was ascertained from 92.0% (13 247/14 399) people from the general population: 38.6% (5113/13 247) were unvaccinated, 26.3% (3484/13 247) were fully vaccinated, and 35.1% (4650/13 247) were partially vaccinated. TBE vaccine effectiveness was 99.5% (98.0-99.9) against TBE, 99.5% (97.9-99.9) against TBE hospitalization, 99.3% (94.8-99.9) against moderate/severe TBE, and 99.2% (94.4-99.9) against TBE hospitalization >12 days. From 2018 to 2020, vaccination averted 906 TBE cases, including 20 deaths. DISCUSSION: TBE vaccine was highly effective in preventing TBE, moderate and severe disease, and prolonged hospitalization. To prevent life-threatening TBE, TBE vaccine uptake and compliance should be increased in Latvia and other European regions where TBE is endemic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Encephalitis, Tick-BorneEncephalitis Viruses, Tick-BorneViral VaccinesAntibodies, ViralVaccinationHumansLatviaFemaleMaleMiddle AgedAdultAdolescentYoung AdultAgedChildChild, PreschoolVaccine EfficacyInfantImmunoglobulin GAged, 80 and overImmunoglobulin M

Stichwörter der Autor:innen

EpidemiologyPreventionTBETick-borne diseasesTick-borne encephalitis

Substanzen

Viral VaccinesAntibodies, ViralImmunoglobulin GImmunoglobulin M

Autor:innen und Institutionen

  • Department of Pediatrics, Children's Clinical University Hospital, Rīga Stradinš University, Riga, Latvia.
  • Department of Neurology and Neurosurgery, Riga East University Hospital, Rīga Stradinš University, Riga, Latvia.
  • Research Department, Rīga Stradinš University, Riga, Latvia.
  • Vaccines/Antivirals & Evidence Generation, Pfizer Vaccines, Collegeville, PA, USA.
  • Vaccines/Antivirals & Evidence Generation, Pfizer Vaccines, Collegeville, PA, USA. Electronic address: frederick.angulo@pfizer.com.
  • Vaccines/Antivirals & Evidence Generation, Pfizer Vaccines, Vienna, Austria.

Zitieren

APA

Zavadska, D., Freimane, Z., Karelis, G., Ermina, I., Harper, L. R., Bender, C., Zhang, P., Angulo, F. J., Erber, W., Bormane, A., Gutmane, E., Litauniece, Z. A., Tihonovs, J., Griskevica, A., Madhava, H., & Jodar, L. (2023). Effectiveness of tick-borne encephalitis vaccination in Latvia, 2018–2020: an observational study. Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2023.06.028

Vancouver

Zavadska D, Freimane Z, Karelis G, Ermina I, Harper LR, Bender C, et al. Effectiveness of tick-borne encephalitis vaccination in Latvia, 2018–2020: an observational study. Clinical Microbiology and Infection. 2023. doi:10.1016/j.cmi.2023.06.028

BibTeX
@article{Zavadska2023,
  author = {Zavadska, Dace and Freimane, Zane and Karelis, Guntis and Ermina, Ineta and Harper, Lisa R and Bender, Cody and Zhang, Pingping and Angulo, Frederick J and Erber, Wilhelm and Bormane, Antra and Gutmane, Evija and Litauniece, Zane A and Tihonovs, Jevgenijs and Griskevica, Aija and Madhava, Harish and Jodar, Luis},
  title = {Effectiveness of tick-borne encephalitis vaccination in Latvia, 2018–2020: an observational study},
  journal = {Clinical Microbiology and Infection},
  year = {2023},
  doi = {10.1016/j.cmi.2023.06.028}
}
Kostenlos starten →